Lorlatinib Exposed: A Far From Optimal Dose
- PMID: 35394660
- DOI: 10.1002/cpt.2579
Lorlatinib Exposed: A Far From Optimal Dose
Comment in
-
Response to "Lorlatinib Exposed: A Far from Optimal Dose".Clin Pharmacol Ther. 2022 Jun;111(6):1197-1198. doi: 10.1002/cpt.2580. Epub 2022 Mar 31. Clin Pharmacol Ther. 2022. PMID: 35358326 No abstract available.
Comment on
-
Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer.Clin Pharmacol Ther. 2021 Nov;110(5):1273-1281. doi: 10.1002/cpt.2228. Epub 2021 Jun 26. Clin Pharmacol Ther. 2021. PMID: 33973232 Free PMC article. Clinical Trial.
References
-
- Chen, J. et al. Lorlatinib exposure-response analyses for safety and efficacy in a phase I/II trial to support benefit-risk assessment in non-small cell lung cancer. Clin. Pharmacol. Ther. 110, 1273-1281 (2021).
-
- Pascual, I. et al. Association of elevated serum triglyceride levels with a more severe course of acute pancreatitis: cohort analysis of 1457 patients. Pancreatology 19, 623-629 (2019).
-
- Camidge, D.R. Lorlatinib should not be considered as the preferred first-line option in patients with advanced ALK rearranged NSCLC. J. Thorac. Oncol. 16, 528-531 (2021).
-
- Ratain, M.J., Tannock, I.F. & Lichter, A.S. Dose optimization of sotorasib: is the US Food and Drug Administration Sending a Message? J. Clin. Oncol. 39, 3423-3426 (2021).
-
- Friends of Cancer Research. Optimizing Dosing in Oncology Drug Development: A Friends of Cancer Research White Paper (Friends of Cancer Research, Washington, DC, 2021).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical

